Pertuzumab: Difference between revisions
Content deleted Content added
m Citations: [Pu158]+: last2, first2, last3, first3, last4, first4, last5, first5, last6, first6, last7, first7, last8, first8, last9, first9. You can use this bot yourself! Report bugs here. |
m protein dimer |
||
| Line 28: | Line 28: | ||
}} |
}} |
||
'''Pertuzumab''' (also called '''2C4''', trade name '''Omnitarg''') is a [[monoclonal antibody]]. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to [[HER2]], it inhibits the [[dimer]]ization of HER2 with other HER receptors, which is hypothesized to result in slowed [[cancer|tumor]] growth.<ref name="JCO-deBono">{{cite journal|last = de Bono|first = Johann S.|title=Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer|journal = Journal of Clinical Oncology|volume=25|issue=3|pages=257–262|date=20 January 2007|id=|doi=10.1200/JCO.2006.07.0888|pmid=17235043|last2 = Bellmunt|first2 = J|last3 = Attard|first3 = G|last4 = Droz|first4 = JP|last5 = Miller|first5 = K|last6 = Flechon|first6 = A|last7 = Sternberg|first7 = C|last8 = Parker|first8 = C|last9 = Zugmaier|first9 = G}}</ref> Pertuzumab is currently being developed by [[Genentech]]. |
'''Pertuzumab''' (also called '''2C4''', trade name '''Omnitarg''') is a [[monoclonal antibody]]. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to [[HER2]], it inhibits the [[protein dimer|dimer]]ization of HER2 with other HER receptors, which is hypothesized to result in slowed [[cancer|tumor]] growth.<ref name="JCO-deBono">{{cite journal|last = de Bono|first = Johann S.|title=Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer|journal = Journal of Clinical Oncology|volume=25|issue=3|pages=257–262|date=20 January 2007|id=|doi=10.1200/JCO.2006.07.0888|pmid=17235043|last2 = Bellmunt|first2 = J|last3 = Attard|first3 = G|last4 = Droz|first4 = JP|last5 = Miller|first5 = K|last6 = Flechon|first6 = A|last7 = Sternberg|first7 = C|last8 = Parker|first8 = C|last9 = Zugmaier|first9 = G}}</ref> Pertuzumab is currently being developed by [[Genentech]]. |
||
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.<ref>[http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=8431 Genentech press release] - May 15, 2005</ref> |
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.<ref>[http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=8431 Genentech press release] - May 15, 2005</ref> |
||
Revision as of 15:02, 29 August 2010
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HER2 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
Pertuzumab (also called 2C4, trade name Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[2] Pertuzumab is currently being developed by Genentech.
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[3]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ de Bono, Johann S.; Bellmunt, J; Attard, G; Droz, JP; Miller, K; Flechon, A; Sternberg, C; Parker, C; Zugmaier, G (20 January 2007). "Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer". Journal of Clinical Oncology. 25 (3): 257–262. doi:10.1200/JCO.2006.07.0888. PMID 17235043.
- ^ Genentech press release - May 15, 2005
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |